Family · Pharmaceutical analytical standards
Pirfenidone
An oral antifibrotic for idiopathic pulmonary fibrosis, a disease in which the lung stiffens through excess scar tissue: first approved in Japan in 2008 and in Europe in 2011. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?In the 1970s it was described as an anti-inflammatory; only in the 1990s was it found to curb collagen production and fibroblast growth in the lungs of laboratory animals.
No product matches your search.
EDQM standards 1
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
